Drug Monitoring Novel Psychoactive Substances (NPS), Qualitative, Urine
Also known as: Benzo Dope Designer Opioids, Tranq Dope Fentanyl Analogs, Carfentanil, Acetyl Fentanyl, Sufentanil
Use
This panel is designed to detect a broad array of novel psychoactive substances (NPS)—designer or synthetic drugs—across six different drug classes in urine. It provides definitive qualitative detection at the class level, identifying misuse and emerging illicit compounds such as designer fentanyl analogs, opioids, stimulants, synthetic cannabinoids and other additives. Results provide a 'positive' or 'negative' classification for each class based on cutoffs (typically 1–20 ng/mL), supporting clinical interpretation alongside patient presentation.
Special Instructions
Testing is performed at the Quest Diagnostics Nichols Institute in Chantilly, Virginia, using LC‑MS/MS. The panel code remains stable even as the list of individual analytes is updated annually. Standalone codes for each NPS class are also available as alternatives to ordering the full panel.
Limitations
This is a qualitative, definitive test and not intended to determine clinical impairment. A positive class result indicates detection of one or more compounds at or above cutoff; a negative result means none were detected above cutoff. It should be interpreted in conjunction with clinical context.
Methodology
Mass Spectrometry
Biomarkers
Other
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
Not provided
Minimum Volume
Not provided